Minneapolis, Minnesota, United States, June 2025 – Piper Q. has joined Celcuity as Vice President, Human Resources, stepping into a critical leadership role to drive the company’s people strategy, foster an inclusive culture, and support organizational growth. In this new position, Piper will oversee talent acquisition, employee engagement, operational efficiency, and innovative HR solutions, reinforcing Celcuity’s commitment to its remote workforce and mission-driven environment.
Prior to joining Celcuity, Piper was Executive Director, Head of Human Resources at ALX Oncology. There, Piper established the HR department from the ground up for a publicly traded clinical-stage immuno-oncology company, managing all aspects of talent, compensation, onboarding, wellness, performance, and culture. Piper partnered closely with the CFO and executive leadership to drive growth, compliance, and cultural sustainability.
Piper’s earlier roles include serving as Senior Director, Human Resources at Eiger BioPharmaceuticals, where Piper led the creation of HR systems and strategy in a fast-scaling, innovation-focused biopharma environment, acting as a trusted advisor to the CEO and Executive Leadership Team. Piper also held significant HR leadership and compliance roles at Biocare Medical, driving global expansion, learning and development, and anti-corruption compliance initiatives.
Throughout a diverse career, Piper has delivered impact as Director, HR & Business at Gaw Van Male, LLP, Manager, HR Operations & Business Partner to R&D at Santen, and in earlier marketing, systems, and consulting roles. Piper is recognized for building people-first, high-performance cultures, driving operational and digital transformation, and implementing robust compensation and rewards programs in biotech, legal, and technology-driven companies.
About Celcuity
Celcuity is a clinical-stage, publicly traded biotechnology company headquartered in Minneapolis, Minnesota, focused on extending the lives of cancer patients through innovative targeted therapies for multiple solid tumor indications. The company’s lead candidate, gedatolisib, is a differentiated first-in-class PI3K/AKT/mTOR pathway inhibitor currently advancing through Phase 3 trials. Celcuity’s science-driven approach is dedicated to treating the cellular drivers of tumor growth and developing advanced therapeutic solutions for cancer care.
Read Also : HR Is Not a Support Function—It’s the CEO’s Most Powerful Growth Engine
The Fine Balance: Navigating Work, Life, and Mental Wellbeing
From Gatekeeping to Gateway Building: Transforming How Organisations Create Access
Leadership In Talent Management: A Powerful Driver for Economic Growth
